<main role="main" class="html-publication" lang="en">
      

  <div class="publication-external">
    <ul class="organisation-logos">
        <li class="organisation-logos__logo">
          <div class="gem-c-organisation-logo brand--department-of-health">
    <a href="/government/organisations/department-of-health-and-social-care" class="gem-c-organisation-logo__container gem-c-organisation-logo__link gem-c-organisation-logo__crest gem-c-organisation-logo__crest--single-identity brand__border-color">
      <span class="gem-c-organisation-logo__name">Department<br>of Health &amp;<br>Social Care</span>
</a>
</div>

        </li>
    </ul>
  </div>

  <header class="gem-c-inverse-header  gem-c-inverse-header--padding-top ">
    
  <div class="gem-c-title gem-c-title--inverse govuk-!-margin-top-8 govuk-!-margin-bottom-0">
    <span class="govuk-caption-xl gem-c-title__context">
      Research and analysis
    </span>
  <h1 class="gem-c-title__text ">
    Lateral flow device specificity in phase 4 (post-marketing) surveillance
  </h1>
</div>
  <p class="publication-header__last-changed">Published 10 March 2021</p>

  </header>




<div class="govuk-grid-row sidebar-with-body" data-module="sticky-element-container">
    <div class="govuk-grid-column-one-quarter-from-desktop contents-list-container">
        <nav data-module="gem-track-click" class="gem-c-contents-list  gem-c-contents-list--no-underline " aria-label="Contents" role="navigation">
    <h2 class="gem-c-contents-list__title">
      Contents
</h2>
    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-action="content_item 1" data-track-label="#summary" data-track-category="contentsClicked" href="#summary" data-track-options="{&quot;dimension29&quot;:&quot;Summary&quot;}" class="gem-c-contents-list__link govuk-link ">Summary</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;Study results&quot;}" class="gem-c-contents-list__link govuk-link " data-track-action="content_item 2" href="#study-results" data-track-label="#study-results" data-track-category="contentsClicked">Study results</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-options="{&quot;dimension29&quot;:&quot;Scenarios compatible with phase 4 findings&quot;}" data-track-action="content_item 3" data-track-category="contentsClicked" data-track-label="#scenarios-compatible-with-phase-4-findings" href="#scenarios-compatible-with-phase-4-findings" class="gem-c-contents-list__link govuk-link ">Scenarios compatible with phase 4 findings</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--numbered">
          <a data-track-label="#conclusion" data-track-options="{&quot;dimension29&quot;:&quot;Conclusion&quot;}" data-track-category="contentsClicked" class="gem-c-contents-list__link govuk-link " data-track-action="content_item 4" href="#conclusion">Conclusion</a>

        </li>
    </ol>
</nav>
      
<div class="gem-c-print-link govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link gem-c-print-link__button">Print this page</button>
</div>
    </div>

  <div class="print-wrapper">
    <div class="print-meta-data">
      <p>
  <img class="print-meta-data-licence" src="/assets/government-frontend/open-government-licence-min-e98134ae65ff5fe99a524d8c383350b3998f91c298dc24b36126e65f1656c578.png">
</p>
<p>
  © Crown copyright 2021
</p>
<p>
  This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit <a href="https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3">nationalarchives.gov.uk/doc/open-government-licence/version/3</a> or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: <a href="mailto:psi@nationalarchives.gov.uk">psi@nationalarchives.gov.uk</a>.
</p>
<p>
  Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
</p>
<p>
  This publication is available at https://www.gov.uk/government/publications/lateral-flow-device-specificity-in-phase-4-post-marketing-surveillance/lateral-flow-device-specificity-in-phase-4-post-marketing-surveillance
</p>


    </div>
  </div>

  <div class="main-content-container">
    <div class="gem-c-govspeak-html-publication">
  
<div data-module="govspeak" class="gem-c-govspeak govuk-govspeak ">
    
    
      <div class="govspeak">
<p>Authors:</p>

<ul>
  <li>
    <p>Achim Wolf, NHS Test and Trace, Department of Health and Social Care</p>
  </li>
  <li>
    <p>Jack Hulmes, NHS Test and Trace, Department of Health and Social Care</p>
  </li>
  <li>
    <p>Susan Hopkins, Public Health England</p>
  </li>
</ul>

<h2>Summary</h2>

<p>Public Health England (<abbr title="Public Health England">PHE</abbr>) and Oxford University evaluated the performance of the Innova <abbr title="lateral flow device">LFD</abbr> device against <abbr title="polymerase chain reaction">PCR</abbr>. In phase 2 and 3a, where the same sample was used for both <abbr title="polymerase chain reaction">PCR</abbr> and <abbr title="lateral flow device">LFD</abbr> specificity analyses, no false positives were detected.</p>

<p>We conducted a phase 4, post-marketing surveillance study in 7,546 individuals with a negative <abbr title="polymerase chain reaction">PCR</abbr> result and compared those results with the <abbr title="lateral flow device">LFD</abbr> results from a separate sample. This study identified 21 (0.28%) discordant test pairs and therefore concluded that the specificity of the <abbr title="lateral flow device">LFD</abbr> device was 99.72%. However, this analysis assumed a sensitivity for the <abbr title="polymerase chain reaction">PCR</abbr> of 100% (that is, that on all 21 discordant samples the <abbr title="polymerase chain reaction">PCR</abbr>, and not the <abbr title="lateral flow device">LFD</abbr>, gave the correct result). Analysis of the phase 4 data can also be interpreted with lower <abbr title="polymerase chain reaction">PCR</abbr> sensitivity levels and is consistent with a <abbr title="polymerase chain reaction">PCR</abbr> sensitivity ranging from 94.2% to 100% and an associated <abbr title="lateral flow device">LFD</abbr> specificity ranging from 100% to 99.72%.</p>

<p>Subsequently we have analysed data from <abbr title="lateral flow device">LFD</abbr> community testing at NHS Test and Trace asymptomatic testing sites (<abbr title="asymptomatic testing sites">ATSs</abbr>) from 20 November 2020 to 27 January 2021: 1,700,972 were conducted and 38,270 (2.2%) LFDs returned a positive result. Among positive <abbr title="lateral flow device">LFD</abbr> results, 25,779 (67%) were matched to a <abbr title="polymerase chain reaction">PCR</abbr> test within the subsequent 5 days. Of those, 24,147 (93.7%) returned a positive <abbr title="polymerase chain reaction">PCR</abbr> result, significantly higher than the positive predictive value expected with <abbr title="lateral flow device">LFD</abbr> specificity of 99.72%. The best statistical fit of this data resulted in <abbr title="lateral flow device">LFD</abbr> specificity of 99.97% and <abbr title="polymerase chain reaction">PCR</abbr> sensitivity of 94.8%. Similar numbers were found in schools (<abbr title="lateral flow device">LFD</abbr> specificity 99.97%, <abbr title="polymerase chain reaction">PCR</abbr> sensitivity 94.4%).</p>

<p>These analyses support the policy of not requiring <abbr title="polymerase chain reaction">PCR</abbr> confirmation of positive <abbr title="lateral flow device">LFD</abbr> tests conducted at <abbr title="asymptomatic testing sites">ATSs</abbr> under current levels of population prevalence. The data will be kept under review and further post-marketing surveillance analyses conducted at regular intervals.</p>

<h2>Study results</h2>

<p>The <abbr title="Public Health England">PHE</abbr> Porton Down/Oxford study evaluated the performance of the Innova <abbr title="lateral flow device">LFD</abbr> device against <abbr title="polymerase chain reaction">PCR</abbr>. For its specificity analyses, it found no false positives in phases 2 and 3, where the same samples were used for both <abbr title="polymerase chain reaction">PCR</abbr> and <abbr title="lateral flow device">LFD</abbr> (0 out of 1,012).<sup role="doc-noteref"><a href="#fn:1" class="govuk-link">[footnote 1]</a></sup></p>

<p>For phase 4, the study compared 8,223 <abbr title="polymerase chain reaction">PCR</abbr> results with <abbr title="lateral flow device">LFD</abbr> results from a second separate sample from 4 different sites (Table 1). These data were extracted from the studies performed at 4 sites in November 2020.</p>

<h3>Table 1: <abbr title="polymerase chain reaction">PCR</abbr> results</h3>

<table>
  <thead>
    <tr>
      <th scope="col">  Site</th>
      <th style="text-align: right" scope="col">PCR+</th>
      <th scope="col" style="text-align: right">PCR-</th>
      <th style="text-align: right" scope="col">PCR total</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th scope="row">  Regional test sites (<abbr title="regional test sites">RTS</abbr>)</th>
      <td style="text-align: right">373</td>
      <td style="text-align: right">1,314</td>
      <td style="text-align: right">1,687</td>
    </tr>
    <tr>
      <th scope="row">  Liverpool community testing</th>
      <td style="text-align: right">88</td>
      <td style="text-align: right">5,438</td>
      <td style="text-align: right">5,526</td>
    </tr>
    <tr>
      <th scope="row">  Manchester evaluation study</th>
      <td style="text-align: right">91</td>
      <td style="text-align: right">314</td>
      <td style="text-align: right">405</td>
    </tr>
    <tr>
      <th scope="row">  York evaluation study</th>
      <td style="text-align: right">125</td>
      <td style="text-align: right">480</td>
      <td style="text-align: right">605</td>
    </tr>
    <tr>
      <th scope="row">  Total</th>
      <td style="text-align: right">677</td>
      <td style="text-align: right">7,546</td>
      <td style="text-align: right">8,223</td>
    </tr>
  </tbody>
</table>

<p>Prevalence based on <abbr title="polymerase chain reaction">PCR</abbr> 8.2% (677/8,223).</p>

<p>7,546 negative <abbr title="polymerase chain reaction">PCR</abbr> results were compared to <abbr title="lateral flow device">LFD</abbr> results. The study identified 21 (0.28%) discordant test pairs and therefore concluded that the specificity of the <abbr title="lateral flow device">LFD</abbr> device was 99.72% (Table 2).</p>

<h3>Table 2: false positive LFDs relative to <abbr title="polymerase chain reaction">PCR</abbr>
</h3>

<table>
  <thead>
    <tr>
      <th scope="col"> Site</th>
      <th style="text-align: right" scope="col">LFD+</th>
      <th style="text-align: right" scope="col">PCR-</th>
      <th style="text-align: right" scope="col">False positive rate</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th scope="row">  Regional test sites (<abbr title="regional test sites">RTS</abbr>)</th>
      <td style="text-align: right">5</td>
      <td style="text-align: right">1,314</td>
      <td style="text-align: right">0.38%</td>
    </tr>
    <tr>
      <th scope="row">  Liverpool community testing</th>
      <td style="text-align: right">3</td>
      <td style="text-align: right">5,438</td>
      <td style="text-align: right">0.06%</td>
    </tr>
    <tr>
      <th scope="row">  Manchester evaluation study</th>
      <td style="text-align: right">4</td>
      <td style="text-align: right">314</td>
      <td style="text-align: right">1.27%</td>
    </tr>
    <tr>
      <th scope="row">  York evaluation study</th>
      <td style="text-align: right">9</td>
      <td style="text-align: right">480</td>
      <td style="text-align: right">1.88%</td>
    </tr>
    <tr>
      <th scope="row">  Total</th>
      <td style="text-align: right">21</td>
      <td style="text-align: right">7,546</td>
      <td style="text-align: right">0.28%</td>
    </tr>
  </tbody>
</table>

<p><abbr title="lateral flow device">LFD</abbr> specificity relative to <abbr title="polymerase chain reaction">PCR</abbr> 99.72%.</p>

<p>However, this assumed that the clinical sensitivity of the <abbr title="polymerase chain reaction">PCR</abbr> was 100%. A recent meta-analysis<sup role="doc-noteref"><a href="#fn:2" class="govuk-link">[footnote 2]</a></sup> found a pooled estimate of 94% (significant heterogeneity, range 42% to 98%). This is likely related to sampling technique, volume of fluid and viral load.</p>

<p>Therefore we modelled the impact of different assumptions of <abbr title="polymerase chain reaction">PCR</abbr> clinical sensitivity on the phase 4 findings of <abbr title="lateral flow device">LFD</abbr> specificity, using the reported data on prevalence (Table 1), discordant <abbr title="polymerase chain reaction">PCR</abbr> negatives (Table 2) and discordant <abbr title="polymerase chain reaction">PCR</abbr> positives (Table 3) using 2 alternative hypotheses:</p>

<ol>
  <li>Assuming 100% <abbr title="polymerase chain reaction">PCR</abbr> sensitivity to estimate <abbr title="lateral flow device">LFD</abbr> specificity</li>
  <li>Assuming 100% <abbr title="lateral flow device">LFD</abbr> specificity to estimate <abbr title="polymerase chain reaction">PCR</abbr> sensitivity</li>
</ol>

<h3>Table 3: true positive LFDs relative to <abbr title="polymerase chain reaction">PCR</abbr>
</h3>

<table>
  <thead>
    <tr>
      <th scope="col">  Site</th>
      <th scope="col" style="text-align: right">LFD+</th>
      <th style="text-align: right" scope="col">PCR+</th>
      <th style="text-align: right" scope="col">Sensitivity</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th scope="row"> Regional test sites (<abbr title="regional test sites">RTS</abbr>)</th>
      <td style="text-align: right">214</td>
      <td style="text-align: right">373</td>
      <td style="text-align: right">57.4%</td>
    </tr>
    <tr>
      <th scope="row">   Liverpool community testing</th>
      <td style="text-align: right">28</td>
      <td style="text-align: right">88</td>
      <td style="text-align: right">31.8%</td>
    </tr>
    <tr>
      <th scope="row">  Manchester evaluation study</th>
      <td style="text-align: right">34</td>
      <td style="text-align: right">91</td>
      <td style="text-align: right">37.4%</td>
    </tr>
    <tr>
      <th scope="row"> York evaluation study</th>
      <td style="text-align: right">63</td>
      <td style="text-align: right">125</td>
      <td style="text-align: right">50.4%</td>
    </tr>
    <tr>
      <th scope="row">  Total</th>
      <td style="text-align: right">339</td>
      <td style="text-align: right">677</td>
      <td style="text-align: right">50.1%</td>
    </tr>
  </tbody>
</table>

<p><abbr title="lateral flow device">LFD</abbr> sensitivity relative to <abbr title="polymerase chain reaction">PCR</abbr> 50.1%.</p>

<p>The assumptions used for the modelling are described in Table 4 below.</p>

<h3>Table 4: modelling assumptions</h3>

<table>
  <thead>
    <tr>
      <td></td>
      <th scope="col">LFD</th>
      <th scope="col">PCR</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th scope="row"> Clinical   sensitivity</th>
      <td>50.1%</td>
      <td>100% - 94.2% (adjusted to maintain consistency with phase 4 results)</td>
    </tr>
    <tr>
      <th scope="row">  Clinical   specificity</th>
      <td>99.72% - 100% (adjusted to maintain consistency with phase 4 results)</td>
      <td>100%</td>
    </tr>
  </tbody>
</table>

<p>The ‘true’ prevalence was adjusted depending on the <abbr title="polymerase chain reaction">PCR</abbr> sensitivity. The ‘<abbr title="polymerase chain reaction">PCR</abbr>’ prevalence reported in phase 4 was 8.2% (Table 1) so in the scenario which assumes a <abbr title="polymerase chain reaction">PCR</abbr> sensitivity of, for example, 95%, the ‘true’ prevalence is adjusted upwards to 8.7% (0.082/0.95) to ensure consistency with the phase 4 findings.</p>

<p>The baseline scenario (<abbr title="polymerase chain reaction">PCR</abbr> clinical sensitivity of 100%, as per phase 4 analysis) is presented in Table 5.</p>

<h3>Table 5: scenario 1 (<abbr title="polymerase chain reaction">PCR</abbr> sensitivity 100%/<abbr title="lateral flow device">LFD</abbr> specificity 99.72%)</h3>

<figure class="image embedded"><div class="img"><img alt="" src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/116370/Table_5.png"></div></figure>

<p>Table 5 shows:</p>

<ul>
  <li>677 individuals with COVID, all of whom were positive on <abbr title="polymerase chain reaction">PCR</abbr>:
    <ul>
      <li>339 of those were also positive on <abbr title="lateral flow device">LFD</abbr>
</li>
      <li>338 were negative on <abbr title="lateral flow device">LFD</abbr>
</li>
    </ul>
  </li>
  <li>7,546 individuals without COVID, all of whom were negative on <abbr title="polymerase chain reaction">PCR</abbr>:
    <ul>
      <li>7,525 individuals were also negative on <abbr title="lateral flow device">LFD</abbr>
</li>
      <li>21 were positive on <abbr title="lateral flow device">LFD</abbr> (discordant pairs)</li>
    </ul>
  </li>
</ul>

<p>In this scenario, there are no <abbr title="polymerase chain reaction">PCR</abbr> false negatives, and the specificity of the <abbr title="lateral flow device">LFD</abbr> device relative to <abbr title="polymerase chain reaction">PCR</abbr> is therefore also the ‘true’ specificity.</p>

<p>At 100% <abbr title="lateral flow device">LFD</abbr> specificity, the <abbr title="polymerase chain reaction">PCR</abbr> sensitivity would need to be 94.2% (Table 6). A <abbr title="polymerase chain reaction">PCR</abbr> sensitivity below 94.2% is not compatible with the phase 4 data as there would be too many <abbr title="polymerase chain reaction">PCR</abbr> false negatives (more than 42) and therefore too many false positive <abbr title="lateral flow device">LFD</abbr> results relative to <abbr title="polymerase chain reaction">PCR</abbr> (that is, more than the 21 observed in the phase 4 results, given the <abbr title="lateral flow device">LFD</abbr> sensitivity of 50.1%).</p>

<h3>Table 6: scenario 2 (<abbr title="polymerase chain reaction">PCR</abbr> sensitivity 94.2%/<abbr title="lateral flow device">LFD</abbr> specificity 100%)</h3>

<figure class="image embedded"><div class="img"><img src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/116371/Table_6.png" alt=""></div></figure>

<p>Table 6 shows:</p>

<ul>
  <li>719 individuals with COVID:
    <ul>
      <li>677 of those were positive on <abbr title="polymerase chain reaction">PCR</abbr>. Of those 677:
        <ul>
          <li>339 were also positive on <abbr title="lateral flow device">LFD</abbr>
</li>
          <li>338 were negative on <abbr title="lateral flow device">LFD</abbr>
</li>
        </ul>
      </li>
      <li>42 were negative on <abbr title="polymerase chain reaction">PCR</abbr>. Of those 42:
        <ul>
          <li>21 were positive on <abbr title="lateral flow device">LFD</abbr> (discordant pairs)</li>
          <li>21 were negative on <abbr title="lateral flow device">LFD</abbr>
</li>
        </ul>
      </li>
    </ul>
  </li>
  <li>7,504 individuals without COVID, all of whom were negative on <abbr title="polymerase chain reaction">PCR</abbr> and negative on <abbr title="lateral flow device">LFD</abbr>.</li>
</ul>

<p>In scenario 2, the numbers reported by phase 4 remain unchanged:</p>

<ul>
  <li>
<abbr title="polymerase chain reaction">PCR</abbr> prevalence of 677 / 8,223, or 8.2%</li>
  <li>677 <abbr title="polymerase chain reaction">PCR</abbr> positives, of which 339 were <abbr title="lateral flow device">LFD</abbr> positive – <abbr title="lateral flow device">LFD</abbr> sensitivity of 50.1%</li>
  <li>7,546 <abbr title="polymerase chain reaction">PCR</abbr> negatives, of which 21 were <abbr title="lateral flow device">LFD</abbr> positive – <abbr title="lateral flow device">LFD</abbr> specificity of 99.72% relative to <abbr title="polymerase chain reaction">PCR</abbr>
</li>
</ul>

<p>However, in this scenario the correct interpretation would be that:</p>

<ul>
  <li>the true prevalence is 719/8,223, or 8.7% (0.082/0.942)</li>
  <li>of the 719 cases, 360 were <abbr title="lateral flow device">LFD</abbr> positive – unchanged <abbr title="lateral flow device">LFD</abbr> sensitivity of 50.1%</li>
  <li>of the 7,504 non-cases, all were <abbr title="lateral flow device">LFD</abbr> negative – ‘true’ <abbr title="lateral flow device">LFD</abbr> specificity of 100%</li>
  <li>in the 21 cases where the <abbr title="polymerase chain reaction">PCR</abbr> was negative but the <abbr title="lateral flow device">LFD</abbr> was positive, the <abbr title="lateral flow device">LFD</abbr> was correct due to the <abbr title="polymerase chain reaction">PCR</abbr> sensitivity of 94.2%</li>
</ul>

<h2>Scenarios compatible with phase 4 findings</h2>

<p>Scenarios 1 and 2 are the 2 extremes of possible interpretations of the results. The results found by phase 4 would also be consistent with a <abbr title="polymerase chain reaction">PCR</abbr> clinical sensitivity ranging from 94.2% to 100% and an <abbr title="lateral flow device">LFD</abbr> specificity ranging from 100% to 99.72% (Table 7).</p>

<h3>Table 7: possible scenarios for <abbr title="polymerase chain reaction">PCR</abbr> clinical sensitivity</h3>

<table>
  <thead>
    <tr>
      <th style="text-align: right" scope="col">PCR     sensitivity</th>
      <th scope="col" style="text-align: right">LFD     specificity</th>
      <th scope="col" style="text-align: right">LFD specificity     relative to PCR</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align: right">100.0%</td>
      <td style="text-align: right">99.72%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">99.5%</td>
      <td style="text-align: right">99.74%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">99.0%</td>
      <td style="text-align: right">99.77%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">98.5%</td>
      <td style="text-align: right">99.79%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">98.0%</td>
      <td style="text-align: right">99.81%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">97.5%</td>
      <td style="text-align: right">99.84%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">97.0%</td>
      <td style="text-align: right">99.86%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">96.5%</td>
      <td style="text-align: right">99.88%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">96.0%</td>
      <td style="text-align: right">99.91%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">95.5%</td>
      <td style="text-align: right">99.93%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">95.0%</td>
      <td style="text-align: right">99.96%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">94.5%</td>
      <td style="text-align: right">99.98%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
    <tr>
      <td style="text-align: right">94.2%</td>
      <td style="text-align: right">100.00%</td>
      <td style="text-align: right">99.72%</td>
    </tr>
  </tbody>
</table>

<p>The PPV of the first <abbr title="lateral flow device">LFD</abbr> test, and the NPV of the confirmatory <abbr title="polymerase chain reaction">PCR</abbr> will vary depending on:</p>

<ol>
  <li>our assumption of the sensitivity of <abbr title="polymerase chain reaction">PCR</abbr>
</li>
  <li>the underlying prevalence of the tested population</li>
</ol>

<p>A range of estimates is presented in Tables 8 and 9.</p>

<h3>Table 8: impact of <abbr title="polymerase chain reaction">PCR</abbr> sensitivity assumptions and prevalence on the PPV of the <abbr title="lateral flow device">LFD</abbr>
</h3>

<table>
  <thead>
    <tr>
      <th scope="col" style="text-align: right">PCR     sensitivity</th>
      <th style="text-align: right" scope="col">LFD     specificity</th>
      <th style="text-align: right" scope="col">PPV of the LFD at 0.5% prevalence</th>
      <th style="text-align: right" scope="col">PPV of the LFD at 1% prevalence</th>
      <th scope="col" style="text-align: right">PPV of the LFD at 2% prevalence</th>
      <th scope="col" style="text-align: right">PPV of the LFD at 5% prevalence</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align: right">100.0%</td>
      <td style="text-align: right">99.72%</td>
      <td style="text-align: right">47%</td>
      <td style="text-align: right">65%</td>
      <td style="text-align: right">79%</td>
      <td style="text-align: right">90%</td>
    </tr>
    <tr>
      <td style="text-align: right">99.5%</td>
      <td style="text-align: right">99.74%</td>
      <td style="text-align: right">50%</td>
      <td style="text-align: right">66%</td>
      <td style="text-align: right">80%</td>
      <td style="text-align: right">91%</td>
    </tr>
    <tr>
      <td style="text-align: right">99.0%</td>
      <td style="text-align: right">99.77%</td>
      <td style="text-align: right">52%</td>
      <td style="text-align: right">68%</td>
      <td style="text-align: right">81%</td>
      <td style="text-align: right">92%</td>
    </tr>
    <tr>
      <td style="text-align: right">98.5%</td>
      <td style="text-align: right">99.79%</td>
      <td style="text-align: right">54%</td>
      <td style="text-align: right">71%</td>
      <td style="text-align: right">83%</td>
      <td style="text-align: right">93%</td>
    </tr>
    <tr>
      <td style="text-align: right">98.0%</td>
      <td style="text-align: right">99.81%</td>
      <td style="text-align: right">57%</td>
      <td style="text-align: right">73%</td>
      <td style="text-align: right">85%</td>
      <td style="text-align: right">93%</td>
    </tr>
    <tr>
      <td style="text-align: right">97.5%</td>
      <td style="text-align: right">99.84%</td>
      <td style="text-align: right">61%</td>
      <td style="text-align: right">76%</td>
      <td style="text-align: right">86%</td>
      <td style="text-align: right">94%</td>
    </tr>
    <tr>
      <td style="text-align: right">97.0%</td>
      <td style="text-align: right">99.86%</td>
      <td style="text-align: right">64%</td>
      <td style="text-align: right">78%</td>
      <td style="text-align: right">88%</td>
      <td style="text-align: right">95%</td>
    </tr>
    <tr>
      <td style="text-align: right">96.5%</td>
      <td style="text-align: right">99.88%</td>
      <td style="text-align: right">68%</td>
      <td style="text-align: right">81%</td>
      <td style="text-align: right">90%</td>
      <td style="text-align: right">96%</td>
    </tr>
    <tr>
      <td style="text-align: right">96.0%</td>
      <td style="text-align: right">99.91%</td>
      <td style="text-align: right">73%</td>
      <td style="text-align: right">85%</td>
      <td style="text-align: right">92%</td>
      <td style="text-align: right">97%</td>
    </tr>
    <tr>
      <td style="text-align: right">95.5%</td>
      <td style="text-align: right">99.93%</td>
      <td style="text-align: right">79%</td>
      <td style="text-align: right">88%</td>
      <td style="text-align: right">94%</td>
      <td style="text-align: right">98%</td>
    </tr>
    <tr>
      <td style="text-align: right">95.0%</td>
      <td style="text-align: right">99.96%</td>
      <td style="text-align: right">86%</td>
      <td style="text-align: right">92%</td>
      <td style="text-align: right">96%</td>
      <td style="text-align: right">98%</td>
    </tr>
    <tr>
      <td style="text-align: right">94.5%</td>
      <td style="text-align: right">99.98%</td>
      <td style="text-align: right">94%</td>
      <td style="text-align: right">97%</td>
      <td style="text-align: right">98%</td>
      <td style="text-align: right">99%</td>
    </tr>
    <tr>
      <td style="text-align: right">94.2%</td>
      <td style="text-align: right">100.00%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">100%</td>
    </tr>
  </tbody>
</table>

<h3>Table 9: impact of <abbr title="polymerase chain reaction">PCR</abbr> sensitivity assumptions and prevalence on the NPV of the <abbr title="polymerase chain reaction">PCR</abbr> confirmatory test</h3>

<table>
  <thead>
    <tr>
      <th scope="col" style="text-align: right">PCR     sensitivity</th>
      <th scope="col" style="text-align: right">LFD     specificity</th>
      <th style="text-align: right" scope="col">NPV of the PCR at 0.5% prevalence</th>
      <th style="text-align: right" scope="col">NPV of the PCR at 1% prevalence</th>
      <th style="text-align: right" scope="col">NPV of the PCR at 2% prevalence</th>
      <th scope="col" style="text-align: right">NPV of the PCR at 5% prevalence</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align: right">100.0%</td>
      <td style="text-align: right">99.72%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">100%</td>
    </tr>
    <tr>
      <td style="text-align: right">99.5%</td>
      <td style="text-align: right">99.74%</td>
      <td style="text-align: right">100%</td>
      <td style="text-align: right">99%</td>
      <td style="text-align: right">98%</td>
      <td style="text-align: right">95%</td>
    </tr>
    <tr>
      <td style="text-align: right">99.0%</td>
      <td style="text-align: right">99.77%</td>
      <td style="text-align: right">99%</td>
      <td style="text-align: right">98%</td>
      <td style="text-align: right">96%</td>
      <td style="text-align: right">90%</td>
    </tr>
    <tr>
      <td style="text-align: right">98.5%</td>
      <td style="text-align: right">99.79%</td>
      <td style="text-align: right">98%</td>
      <td style="text-align: right">97%</td>
      <td style="text-align: right">93%</td>
      <td style="text-align: right">84%</td>
    </tr>
    <tr>
      <td style="text-align: right">98.0%</td>
      <td style="text-align: right">99.81%</td>
      <td style="text-align: right">97%</td>
      <td style="text-align: right">95%</td>
      <td style="text-align: right">90%</td>
      <td style="text-align: right">78%</td>
    </tr>
    <tr>
      <td style="text-align: right">97.5%</td>
      <td style="text-align: right">99.84%</td>
      <td style="text-align: right">96%</td>
      <td style="text-align: right">93%</td>
      <td style="text-align: right">86%</td>
      <td style="text-align: right">71%</td>
    </tr>
    <tr>
      <td style="text-align: right">97.0%</td>
      <td style="text-align: right">99.86%</td>
      <td style="text-align: right">95%</td>
      <td style="text-align: right">90%</td>
      <td style="text-align: right">82%</td>
      <td style="text-align: right">64%</td>
    </tr>
    <tr>
      <td style="text-align: right">96.5%</td>
      <td style="text-align: right">99.88%</td>
      <td style="text-align: right">93%</td>
      <td style="text-align: right">87%</td>
      <td style="text-align: right">76%</td>
      <td style="text-align: right">56%</td>
    </tr>
    <tr>
      <td style="text-align: right">96.0%</td>
      <td style="text-align: right">99.91%</td>
      <td style="text-align: right">90%</td>
      <td style="text-align: right">82%</td>
      <td style="text-align: right">69%</td>
      <td style="text-align: right">46%</td>
    </tr>
    <tr>
      <td style="text-align: right">95.5%</td>
      <td style="text-align: right">99.93%</td>
      <td style="text-align: right">86%</td>
      <td style="text-align: right">75%</td>
      <td style="text-align: right">59%</td>
      <td style="text-align: right">36%</td>
    </tr>
    <tr>
      <td style="text-align: right">95.0%</td>
      <td style="text-align: right">99.96%</td>
      <td style="text-align: right">77%</td>
      <td style="text-align: right">62%</td>
      <td style="text-align: right">45%</td>
      <td style="text-align: right">24%</td>
    </tr>
    <tr>
      <td style="text-align: right">94.5%</td>
      <td style="text-align: right">99.98%</td>
      <td style="text-align: right">55%</td>
      <td style="text-align: right">38%</td>
      <td style="text-align: right">23%</td>
      <td style="text-align: right">10%</td>
    </tr>
    <tr>
      <td style="text-align: right">94.2%</td>
      <td style="text-align: right">100.00%</td>
      <td style="text-align: right">0%</td>
      <td style="text-align: right">0%</td>
      <td style="text-align: right">0%</td>
      <td style="text-align: right">0%</td>
    </tr>
  </tbody>
</table>

<p>The results for NPV on confirmatory <abbr title="polymerase chain reaction">PCR</abbr> are conservative and the NPV is likely to be lower if the confirmatory <abbr title="polymerase chain reaction">PCR</abbr> is, for example, done on the following day.</p>

<p>Furthermore, we analysed data from NHS Test and Trace <abbr title="asymptomatic testing sites">ATSs</abbr> using LFDs from 20 November 2020 to 27 January 2021; 1,700,972 LFDs were performed and 38,270 (2.2%) were reported as positive. Among positive <abbr title="lateral flow device">LFD</abbr> results, 25,779 (67%) were matched to a <abbr title="polymerase chain reaction">PCR</abbr> test within the subsequent 5 days; 24,147 (93.7%) were reported as SARS-CoV-2 <abbr title="polymerase chain reaction">PCR</abbr> positive, significantly higher than the predicted value of 87.2% expected from an <abbr title="lateral flow device">LFD</abbr> specificity of 99.72% (p&lt;0.001).</p>

<p>The observed PPV of the Innova <abbr title="lateral flow device">LFD</abbr> device (based on % of follow-up PCRs returning positive) was significantly higher than expected (i.e. if assuming 99.7% specificity). Figure 1 shows the expected <abbr title="polymerase chain reaction">PCR</abbr> positivity rate against the observed <abbr title="polymerase chain reaction">PCR</abbr> positivity rate, based on Community ATS data (up to 27 January 2021 when confirmatory <abbr title="polymerase chain reaction">PCR</abbr> was suspended). Each data point/bubble represents one day with bubble size dependent on number of confirmatory PCRs that day (‘perfect fit’ would be bubbles aligning on the central red line).</p>

<h3>Figure 1: expected vs observed <abbr title="polymerase chain reaction">PCR</abbr> positivity rate (based on phase 4 data)</h3>

<figure class="image embedded"><div class="img"><img alt="" src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/116389/Figure_1.png"></div></figure>

<p>A different way to visualise this is to plot the difference between expected and observed <abbr title="polymerase chain reaction">PCR</abbr> positivity rate (where perfect fit would be on the red 0% line, i.e. no difference between expected and observed values). As above, each data point is a day of testing, and the x-axis is <abbr title="polymerase chain reaction">PCR</abbr> sample size on that day. Figure 2 shows Observed <abbr title="polymerase chain reaction">PCR</abbr> Positivity being significantly higher than Expected <abbr title="polymerase chain reaction">PCR</abbr> Positivity.</p>

<h3>Figure 2: difference between expected and observed <abbr title="polymerase chain reaction">PCR</abbr> positivity rate (based on 100% <abbr title="polymerase chain reaction">PCR</abbr> sensitivity)</h3>

<p>(<abbr title="lateral flow device">LFD</abbr> specificity 99.72% - <abbr title="polymerase chain reaction">PCR</abbr> sensitivity 100%)</p>

<figure class="image embedded"><div class="img"><img alt="" src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/116347/figure-2-expected-v-observed-pcr-positivity-100-pcr-sensitivity.png"></div></figure>

<p>Expected <abbr title="polymerase chain reaction">PCR</abbr> Positivity rates were then recalculated using different combinations of <abbr title="lateral flow device">LFD</abbr> specificity and <abbr title="polymerase chain reaction">PCR</abbr> sensitivity (as per Table 7 above). The optimal fit to observed data (based on weighted least squares) was at <abbr title="lateral flow device">LFD</abbr> specificity of 99.97% and <abbr title="polymerase chain reaction">PCR</abbr> sensitivity of 94.8%, as seen in Figure 3 below.</p>

<h3>Figure 3: difference between expected and observed <abbr title="polymerase chain reaction">PCR</abbr> positivity rate (based on optimal statistical fit)</h3>

<p>(<abbr title="lateral flow device">LFD</abbr> specificity 99.97% - <abbr title="polymerase chain reaction">PCR</abbr> sensitivity 94.8%)</p>

<figure class="image embedded"><div class="img"><img src="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/image_data/file/116348/figure-3-expected-v-observed-pcr-positivity-optimal-statistical-fit.png" alt=""></div></figure>

<p>The same optimal fit for <abbr title="lateral flow device">LFD</abbr> specificity (99.97%) was found when restricting the analyses to <abbr title="polymerase chain reaction">PCR</abbr> tests taken within in a shorter time period (within one, two, three, or four days of the <abbr title="lateral flow device">LFD</abbr> test).</p>

<p>As noted above, 67% of positive <abbr title="lateral flow device">LFD</abbr> tests had a linked <abbr title="polymerase chain reaction">PCR</abbr> test, 33% did not. Differences in disease status may exist between individuals who go on to get a <abbr title="polymerase chain reaction">PCR</abbr> and those who do not. However, the PPV in individuals who go on to get a confirmatory <abbr title="polymerase chain reaction">PCR</abbr> is key in evaluating the impact of a confirmatory <abbr title="polymerase chain reaction">PCR</abbr> policy.</p>

<p>Analyses were repeated using data from the same time period in School/College testing where 999,353 LFDs were performed and 2,332 (0.23%) were reported as positive. Among positive <abbr title="lateral flow device">LFD</abbr> results, 1,948 (84%) were matched to a <abbr title="polymerase chain reaction">PCR</abbr> test within the subsequent 5 days; 1,576 (80.9%) were reported as SARS-CoV-2 <abbr title="polymerase chain reaction">PCR</abbr> positive. The optimal fit to observed data was at <abbr title="lateral flow device">LFD</abbr> specificity of 99.97% and <abbr title="polymerase chain reaction">PCR</abbr> sensitivity of 94.4%.</p>

<h2>Conclusion</h2>

<p>These analyses support the policy of not requiring <abbr title="polymerase chain reaction">PCR</abbr> confirmation of positive LFDs conducted at <abbr title="asymptomatic testing sites">ATSs</abbr> under current levels of population prevalence. The data will be kept under review and further post marketing surveillance analyses conducted at regular intervals.</p>

<div class="footnotes" role="doc-endnotes">
  <ol>
    <li role="doc-endnote">
      <p><a href="https://www.ox.ac.uk/sites/files/oxford/media_wysiwyg/UK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf" class="govuk-link" rel="external">Preliminary report from the joint <abbr title="Public Health England">PHE</abbr> Porton Down and University of Oxford SARS-CoV-2 test development and validation cell: rapid evaluation of lateral flow viral antigen detection devices (LFDs) for mass community testing</a>.&nbsp;<a role="doc-backlink" aria-label="go to where this is referenced" href="#fnref:1" class="govuk-link">↩</a></p>
    </li>
    <li role="doc-endnote">
      <p><a class="govuk-link" href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0242958#pone-0242958-t002" rel="external">False-negative results of initial RT-<abbr title="polymerase chain reaction">PCR</abbr> assays for COVID-19: A systematic review</a>.&nbsp;<a aria-label="go to where this is referenced" role="doc-backlink" href="#fnref:2" class="govuk-link">↩</a></p>
    </li>
  </ol>
</div>
</div>


</div>
</div>
  </div>

  <div class="sticky-element" data-sticky-element="">
    <a href="#contents" class="govuk-link app-c-back-to-top dont-print">
    <svg xmlns="http://www.w3.org/2000/svg" class="app-c-back-to-top__icon" width="13" height="17" viewBox="0 0 13 17">
      <path d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z" fill="currentColor"></path>
    </svg>
    Contents
</a>

    <div class="sticky-element__print-link">
      
<div class="gem-c-print-link govuk-!-margin-top-0 govuk-!-margin-bottom-6">
    <button data-module="print-link" class="govuk-link gem-c-print-link__button">Print this page</button>
</div>
    </div>
  </div>
</div>

    </main>